Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study Authors: Aleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, Anna Polakiewicz-Gilowska, Renata Soumarová, Miloš Holánek, Hana Študentová, Agnieszka Młodzińska, Karolina Winsko-Szczęsnowicz, Maja Lisik-Habib, Anika Pękala, Daniel Krejčí, Jan Šustr, Iveta Kolářová, Iwona Danielewicz, Magdalena Szymanik-Resko, Tomasz Ciszewski, Lenka Rušinová, Bogumiła Czartoryska-Arłukowicz, Aleksandra Łacko, Michał Jarząb, Marcin Kubeczko, Renata Pacholczak-Madej, Joanna Smok-Kalwat, Zbigniew Nowecki, Zuzana Bielčiková, Miroslava Malejčíková, Mirosława Püsküllüoğlu Published: 2026 ABSTRACT AbstractBackgroundOlder adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited.Materials and methodsWe conducted a retrospective, multinational study across 18 oncology centers in Central Europe, including patients with mTNBC treated with SG between August 2021 and May 2025. Patients were stratified by age at SG initiation: <65 vs ≥65 years. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), treatment modifications, and safety.ResultsAmong 303 patients, 76 (25.1%) were aged ≥65 years. Older patients had more comorbidities, more prior palliative treatment lines, and more frequent ECOG performance status ≥1. In unadjusted analyses, patients aged ≥65 years had longer median OS (12.8 vs 10.9 months; HR, 0.70; 95% CI, 0.49-0.99; P = 0.045) and PFS (5.4 vs 4.1 months; HR, 0.73; 95% CI, 0.54-0.97; P = 0.031). ORR, DCR, treatment modifications, and grade ≥3 neutropenia were comparable between groups. In multivariable analyses, age was not independently associated with OS or PFS.ConclusionIn this selected real-world cohort, patients aged ≥65 years who received SG had outcomes at least comparable to those of younger patients, without an apparent excess severe toxicity. Survival differences were likely influenced by baseline disease characteristics and patient selection rather than chronological age alone.Keywords: metastatic triple-negative breast cancer, older patients, geriatric oncology, sacituzumab govitecan, real-world data Older adults with metastatic triple-negative breast cancer are underrepresented in trials of modern systemic therapies. In this multinational real-world cohort, selected patients aged ≥65 years treated with sacituzumab govitecan had outcomes at least comparable to those of younger patients, without an apparent increase in severe toxicity. However, age was not independently associated with survival after adjustment, suggesting that treatment decisions should not rely on chronological age alone. Baseline disease characteristics, comorbidities, performance status, patient preferences, and, when feasible, geriatric assessment should inform individualized use of sacituzumab govitecan in older adults. Introduction Metastatic triple-negative breast cancer (mTNBC) remains one of the most aggressive subtypes of breast cancer and is associated with poor clinical outcomes.1 Although treatment options for mTNBC have expanded in recent years with the introduction of immune checkpoint inhibitors and antibody-drug conjugates (ADCs), prognosis in the metastatic setting remains unfavorable.2 Among these novel therapies, sacituzumab govitecan (SG), a Trop-2-directed ADC, has significantly changed the treatment landscape for pretreated mTNBC. In the ASCENT trial, SG demonstrated a robust improvement in progression-free survival (PFS) and overall survival (OS) compared with physician’s choice chemotherapy, establishing it as a standard of care in this setting.3 Epidemiologic studies suggest that TNBC demonstrates a bimodal age distribution, with incidence peaks observed among both younger and older women.4 While early-onset TNBC is frequently associated with BRCA1/2 pathogenic variants and highly proliferative disease, late-onset TNBC may represent a biologically distinct subgroup characterized by different metastatic patterns, comorbidity burden, and treatment tolerance.5,6 Older adults represent a substantial proportion of the mTNBC population but remain consistently underrepresented in clinical trials evaluating novel systemic therapies, including ADCs.7,8 In the ASCENT trial, approximately 20% of enrolled patients were aged ≥65 years, whereas patients aged ≥75 years were only minimally represented.9 Although subgroup analyses suggested maintained efficacy and manageable toxicity of SG in older patients, participants in clinical trials often represent a highly selected population, limiting the generalizability of these findings to routine clinical practice.10 Real-world evidence regarding the effectiveness and tolerability of SG in older adults remains limited, particularly in patients aged ≥75 years.11 Current geriatric oncology guidelines emphasize that treatment decisions in older patients should be guided by biological rather than chronological age, integrating functional status, comorbidities, and geriatric assessment whenever feasible.12–14 However, geriatric assessment remains markedly underutilized in routine oncology practice, particularly in patients receiving modern systemic therapies. This multinational retrospective study aimed to evaluate the real-world effectiveness and safety of SG in older patients with mTNBC treated across Central European oncology centers. We performed an age-stratified analysis comparing outcomes between patients aged <65 and ≥65 years and conducted exploratory sensitivity analyses using alternative age thresholds. We also evaluated clinical factors associated with survival and treatment outcomes in routine practice. Materials and methods Study design and setting This was a retrospective, multinational, real-world study conducted across 18 oncology centers in Poland, the Czech Republic, and Slovakia within the Central European Breast Cancer Collaboration (CEBCC) initiative. The CEBCC-102 study included consecutive female patients with histologically confirmed metastatic triple-negative breast cancer (mTNBC) who received sacituzumab govitecan (SG) between August 2021 and May 2025 in routine clinical practice. The study was designed and reported in accordance with the principles of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement and, where applicable, the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) recommendations. Patient eligibility Eligible patients were ≥18 years of age, had histologically confirmed mTNBC, received at least 1 dose of SG, and had available baseline and follow-up data. Patients were stratified according to age at SG initiation: <65 vs ≥65 years. The age threshold of 65 years was selected as the primary cutoff because it is commonly used in oncology studies and was consistent with previous subgroup analyses of SG. Sensitivity analyses were conducted using alternative age thresholds, including <70 vs ≥70 years. An exploratory descriptive analysis was also conducted in patients aged ≥75 years; because of the limited sample size, this analysis was not intended for inferential interpretation. Patients with missing baseline or follow-up data were excluded only from the specific analyses requiring those variables. Denominators are therefore provided separately for each endpoint and table, and the distribution of evaluable patients is summarized in Table S7. Data collection Clinical information was obtained from electronic medical records at participating institutions using a standardized study database. Collected variables included demographic and clinical characteristics, ECOG performance status, comorbidities, germline BRCA1/2 status, prior palliative systemic treatment lines, metastatic sites, including visceral and central nervous system involvement, SG starting dose, number of cycles, dose reductions, treatment delays, G-CSF use, tumor response, survival outcomes, and treatment-related adverse events. Tumor response was assessed locally according to RECIST version 1.1 based on radiological reports available in routine practice.15 Imaging intervals were not protocol-mandated and followed local institutional practice. Adverse events were graded according to CTCAE version 5.0. Information on geriatric assessment was extracted retrospectively from medical records. GA was not mandated by the study protocol and was performed according to local practice. When available, the type of tool, timing relative to SG initiation, assessed domains, and GA-driven interventions were collected; however, these elements were not consistently documented across centers. Therefore, GA was analyzed only as a descriptive process variable and not as a predictor of treatment efficacy. Endpoints The primary endpoints were OS, defined as the time from SG initiation to death from any cause, and PFS, defined as the time from SG initiation to radiological progression or death, whichever occurred first. Patients without an event were censored at the last follow-up. Secondary endpoints included ORR, DCR, CBR, DOR, and safety. ORR was defined as complete or partial response, DCR as complete response, partial response, or stable disease, CBR as disease control lasting at least 6 months, and DOR as the time from first documented response to progression or death among responders. Statistical analysis Baseline characteristics were summarized using descriptive statistics. Categorical variables were compared using the χ2 test or Fisher’s exact test, as appropriate, and continuous variables using the Mann–Whitney U test. Survival outcomes were estimated using the Kaplan–Meier method and compared using the log-rank test. Median follow-up was calculated from SG initiation and summarized overall and by age group. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. The proportional hazards assumption was assessed using Schoenfeld residuals. Age was analyzed as a categorical variable for the primary comparison (<65 vs ≥65 years) and as a continuous variable in additional Cox regression analyses. Multivariable Cox models were adjusted for clinically relevant prognostic factors, including age, ECOG performance status, metastatic burden, BRCA1/2 status, number of prior palliative systemic therapy lines, time from metastatic disease diagnosis to SG initiation, and comorbidities. Sensitivity analyses included an alternative age cutoff of 70 years and propensity score matching for the primary age-group comparison. Exploratory analyses in patients aged ≥75 years and analyses related to geriatric assessment were presented descriptively due to limited sample size and potential selection bias. All tests were 2-sided, and P < 0.05 was considered statistically significant. Statistical analyses were performed using R software, version 4.3.3 (R Foundation for Statistical Computing, Vienna, Austria). Ethical considerations The study was approved by the institutional ethics committees of participating centers in Poland, the Czech Republic, and Slovakia. The study was conducted in accordance with the Declaration of Helsinki and applicable national regulations. Given the retrospective nature of the study and the use of deidentified data, the requirement for written informed consent was waived according to local institutional policies. Results Patient characteristics A total of 303 patients were included. Among them, 76 patients (25.1%) were aged ≥65 years, and 11 patients (3.6%) were aged ≥75 years. The median age at SG initiation was 56 years (range, 27-84). Compared with patients aged <65 years, patients aged ≥65 years more frequently had documented comorbidities, poorer ECOG performance status, and a greater number of prior palliative systemic treatment lines. They also had a longer interval between metastatic disease diagnosis and SG initiation. Conversely, patients aged <65 years more frequently had documented BRCA1/2 pathogenic variants and central nervous system (CNS) or visceral metastases, suggesting differences in baseline disease biology and metastatic burden between age groups. Baseline clinical and demographic characteristics are summarized in Table 1. Table 1.Baseline patient characteristics by age group (<65 vs ≥65 years).Characteristic<65 years (n = 227)≥65 years (n = 76) P-value Median age at SG initiation, years (range) 52 (27-64)70 (65-84)Not applicable Performance status (%) .026 0 103 (45.4)22 (28.9) 1 116 (51.1)50 (65.8) 2-3 7 (3.1)4 (5.3) Missing 1 (0.4)0 Relevant comorbidities (%) 84 (37.0)53 (69.7)<.001 Prior palliative systemic therapy lines .039 Mean (SD) 1.7 (+/−1.1)1.9 (+/−1.2) Median (IQR) 1 (1-2)2 (1-2) BRCA1/2 status (%) <.001 Pathogenic/likely pathogenic variant 34 (15.0)2 (2.6) No BRCA1/2 pathogenic variant detected 175 (77.1)53 (69.7) Not tested 18 (7.9)21 (27.6) Metastatic sites (%) Visceral 176 (77.5)46 (60.5).006 CNS 26 (11.5)2 (2.6).038 Menopausal status (%) Not applicable Premenopausal 113 (49.8)0 Postmenopausal 114 (50.2)76 (100.0) Initial treatment intention at BC diagnosis (%) .333 Curative 184 (81.1)57 (75.0) Palliative 43 (18.9)19 (25.0) Time from BC diagnosis to SG (years), median (IQR) 2.48 (1.52-4.23)3.24 (1.62-5.07).091 Time from advanced BC diagnosis to SG (years), median (IQR) 0.78 (0.44-1.48)1.12 (0.63-2.03).004Abbreviations: BC, breast cancer; BRCA1/2, breast cancer susceptibility genes 1 and 2; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; SG, sacituzumab govitecan; SD, standard deviation. P-values were calculated for between-group comparisons. P-values were not calculated for age and menopausal status because these variables were directly related to age-based stratification. Percentages were calculated using the total number of patients in each age group unless otherwise indicated. Baseline patient characteristics by age group (<65 vs ≥65 years). Abbreviations: BC, breast cancer; BRCA1/2, breast cancer susceptibility genes 1 and 2; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; SG, sacituzumab govitecan; SD, standard deviation. P-values were calculated for between-group comparisons. P-values were not calculated for age and menopausal status because these variables were directly related to age-based stratification. Percentages were calculated using the total number of patients in each age group unless otherwise indicated. Treatment exposure Treatment exposure and dose modifications are summarized in Table 2. The median number of SG cycles and administrations did not differ significantly between age groups. Patients aged ≥65 years were numerically more likely to start SG at a reduced dose and to require dose reductions or treatment delays due to adverse events, although these differences were not statistically significant. Rates of grade ≥3 neutropenia, primary G-CSF prophylaxis, and any G-CSF use were also similar between age groups. G-CSF use was not protocol-mandated and reflected local real-world supportive-care practice. Table 2.Treatment exposure and modifications.Characteristic<65 years (n = 227)≥65 years (n = 76) P-value Starting SG dose ≤ 8 mg/kg, n (%) 17 (7.5)10 (13.2).204 SG dose reduction due to AEs, n (%) 79 (34.8)35 (46.1).106 SG administration delays due to AEs, n (%) 137 (60.4)54 (71.1).125 Grade ≥3 neutropenia, n (%) 104 (45.8)32 (42.1).733 G-CSF in primary prophylaxis, n (%) 76 (33.5)24 (31.6).870 Any G-CSF use, n (%) 161 (70.9)57 (75.0).591 Number of SG cycles .240 Median (IQR) 6 (3-10)7 (3-12) Number of SG administrations .156 Median (IQR) 12 (6-20)15 (6-25) P-values were calculated for between-group comparisons using the chi-square or Fisher’s exact test for categorical variables and the Mann–Whitney U test for continuous variables. Values are shown as n (%) unless otherwise indicated.Abbreviations: AE, adverse event; G-CSF, granulocyte colony-stimulating factor; IQR, interquartile range; n, group size; P-value for between-group comparison; SG, sacituzumab govitecan. Treatment exposure and modifications. P-values were calculated for between-group comparisons using the chi-square or Fisher’s exact test for categorical variables and the Mann–Whitney U test for continuous variables. Values are shown as n (%) unless otherwise indicated. Abbreviations: AE, adverse event; G-CSF, granulocyte colony-stimulating factor; IQR, interquartile range; n, group size; P-value for between-group comparison; SG, sacituzumab govitecan. Survival and response outcomes by age group Treatment outcomes according to age group are summarized in Table 3. In unadjusted analyses, patients aged ≥65 years had longer median OS and PFS than patients aged <65 years. Median OS was 12.8 months vs 10.9 months, respectively (HR, 0.696; 95% CI, 0.488-0.992; log-rank P = 0.045) and median PFS was 5.4 months vs 4.1 months, respectively (HR, 0.725; 95% CI, 0.541-0.971; log-rank P = 0.031). Twelve-month OS and PFS rates were also numerically higher in the older cohort. Median follow-up from SG initiation was 8.90 months (IQR, 4.52-14.49) in the overall cohort, 8.76 months (IQR, 4.20-13.74) in patients aged <65 years, and 9.13 months (IQR, 4.94-16.53) in patients aged ≥65 years. Table 3.Unadjusted treatment outcomes by age group (<65 vs ≥65 years).OutcomeAge <65Age ≥65 P-valueHR (95% CI) Overall survival (OS) Patients/events, n 224/14475/39 Median OS, months 10.912.80.0450.696 (0.488-0.992) 12-month OS 43.3%54.6%—— Progression-free survival (PFS) Patients/events, n 226/19476/59 Median PFS, months 4.15.40.0310.725 (0.541-0.971) 12-month PFS 13.5%25.9%—— Overall response rate (ORR) 30.8%30.3%1.000— Disease control rate (DCR) 61.7%72.4%0.122— Clinical benefit rate (CBR ≥6 months) 22.3%32.4%0.130— Duration of response (DOR), months, median 4.83.70.101—Abbreviations: CBR, clinical benefit rate; CI, confidence interval; DCR, disease control rate; DOR, duration of response; HR, hazard ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. Unadjusted treatment outcomes by age group (<65 vs ≥65 years). Abbreviations: CBR, clinical benefit rate; CI, confidence interval; DCR, disease control rate; DOR, duration of response; HR, hazard ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. ORR and DCR were comparable between age groups. CBR was numerically higher among patients aged ≥65 years, but the difference was not statistically significant. No significant difference was observed in DOR. For OS and PFS, P-values were calculated using the log-rank test, and HRs using univariable Cox proportional hazards models. Response outcomes were calculated in evaluable patients. ORR and DCR were assessed in 227 patients aged <65 years and 76 patients aged ≥65 years. CBR was assessed in 211 and 68 patients, respectively. DOR was calculated among responders with available data for response duration: 67 patients aged <65 years and 23 patients aged ≥65 years. Multivariable Cox regression analyses incorporating age as a continuous variable, ECOG performance status, metastatic burden, BRCA1/2 status, prior palliative systemic treatment lines, time from metastatic disease diagnosis to SG initiation, and comorbidities are presented in Table 4. Table 4.Multivariable Cox proportional hazards models for overall survival and progression-free survival.VariableOS HR (95% CI) P-valuePFS HR (95% CI) P-value Age at SG initiation, per year 0.994 (0.981-1.007)0.3550.996 (0.985-1.008)0.529 ECOG PS 0 Reference—Reference— ECOG PS 1 vs 0 1.878 (1.357-2.599)<0.0010.967 (0.742-1.260)0.804 ECOG PS 2-3 vs 0 8.902 (4.224-18.762)<0.0014.314 (2.234-8.330)<0.001 Lung, liver, or CNS metastases 1.798 (1.251-2.586)0.0021.680 (1.240-2.276)0.001 No BRCA1/2 pathogenic variant detected Reference—Reference— BRCA1/2 pathogenic/likely pathogenic variant 1.708 (1.034-2.821)0.0361.325 (0.885-1.984)0.171 BRCA1/2 not tested 0.973 (0.610-1.549)0.9070.840 (0.562-1.258)0.398 One prior palliative systemic therapy line Reference—Reference— ≥2 prior palliative systemic therapy lines 1.427 (1.037-1.963)0.0291.244 (0.951-1.627)0.112 Time from metastatic disease diagnosis to SG initiation, per year 0.700 (0.591-0.829)<0.0010.881 (0.777-0.999)0.048 Relevant comorbidities 1.113 (0.811-1.528)0.5081.040 (0.793-1.365)0.776The OS model included 295 patients and 180 death events. The PFS model included 298 patients and 249 progression or death events. Variables were selected a priori based on clinical relevance and reviewer recommendations, subject to availability and completeness in the retrospective dataset.Abbreviations: CI, confidence interval; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SG, sacituzumab govitecan. Multivariable Cox proportional hazards models for overall survival and progression-free survival. The OS model included 295 patients and 180 death events. The PFS model included 298 patients and 249 progression or death events. Variables were selected a priori based on clinical relevance and reviewer recommendations, subject to availability and completeness in the retrospective dataset. Abbreviations: CI, confidence interval; CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SG, sacituzumab govitecan. Age was not independently associated with OS (HR, 0.994; 95% CI, 0.981-1.007; P = 0.355) or PFS (HR, 0.996; 95% CI, 0.985-1.008; P = 0.529). Poor performance status and the presence of lung, liver, or CNS metastases were independently associated with worse outcomes. A longer interval from metastatic disease diagnosis to SG initiation was associated with more favorable OS and PFS, likely reflecting differences in disease trajectory and patient selection. No evidence of violation of the proportional hazards assumption was observed for the main Cox models. Kaplan–Meier survival analyses Kaplan–Meier curves for OS and PFS according to age group are shown in Figure 1. In unadjusted analyses, patients aged ≥65 years had longer OS and PFS than patients aged <65 years. Median OS was 12.8 vs 10.9 months, respectively (HR, 0.696; 95% CI, 0.488-0.992; log-rank P = 0.045) and median PFS was 5.4 vs 4.1 months, respectively (HR, 0.725; 95% CI, 0.541-0.971; log-rank P = 0.031). Kaplan–Meier survival curves according to age at SG initiation (<65 vs ≥65 years). (A) Overall survival from SG initiation. (B) Progression-free survival from SG initiation. Numbers at risk are shown below each panel. Sensitivity analyses Using an alternative age cutoff of 70 years, no statistically significant differences were observed in OS (HR, 0.737; 95% CI, 0.447-1.214; P = 0.231) or PFS (HR, 0.752; 95% CI, 0.499-1.133; P = 0.173). In a propensity score-matched sensitivity analysis including ECOG performance status, lung, liver, or CNS metastases, BRCA1/2 status, prior palliative systemic treatment lines, and comorbidities, 76 patients aged ≥65 years were matched to 76 patients aged <65 years. After matching, the association between age ≥65 years and survival outcomes was attenuated and was no longer statistically significant for either OS (HR, 0.741; 95% CI, 0.485-1.132; P = 0.165) or PFS (HR, 0.807; 95% CI, 0.564-1.154; P = 0.240). Detailed matching characteristics and survival estimates are presented in Table S6. Exploratory analyses in patients aged ≥75 years are presented in the Supplementary Materials and should be interpreted with caution because of the very limited sample size. Safety The incidence of grade ≥3 neutropenia was comparable between age groups. Rates of grade ≥3 gastrointestinal, hepatic, and hematologic toxicities were generally low and did not differ significantly between patients aged <65 and ≥65 years. Fatigue and diarrhea were numerically more frequent among older patients, but these differences were not statistically significant. No new safety signals were observed in patients aged ≥65 years. Detailed treatment-related adverse event data are summarized in Table 5. Table 5.Treatment-related adverse events by age group (<65 vs ≥65 years).Adverse eventAll grades <65, n (%)All grades ≥65, n (%)Grade ≥3 <65, n (%)Grade ≥3 ≥ 65, n (%) P-value for grade ≥3 comparison Neutropenia 146 (64.4)53 (70.2)104 (45.8)32 (42.1)0.73 Anemia 88 (38.8)29 (38.1)15 (6.8)5 (7.1)0.68 Fatigue 82 (36.1)32 (41.7)17 (7.3)7 (9.5)0.51 Diarrhea 39 (17.4)19 (25.0)8 (3.7)5 (7.1)0.32 Nausea 52 (22.8)18 (23.8)6 (2.7)2 (2.4)0.89 Vomiting 23 (10.0)7 (9.5)4 (1.8)1 (1.2)0.81 Liver toxicity 39 (17.4)9 (11.9)5 (2.3)2 (2.4)0.79 Thrombocytopenia 19 (8.2)9 (11.9)7 (3.2)5 (6.0)0.47 Allergic reaction 13 (5.9)4 (4.8)5 (2.3)3 (3.6)0.64 Febrile neutropenia 9 (4.1)3 (3.6)7 (3.2)3 (3.6)0.88 Alopecia 107 (47.0)32 (41.7)———Adverse events were graded according to CTCAE version 5.0. Values are shown as n (%). P-values refer to comparisons of grade ≥3 adverse events between age groups. P-values were not calculated for alopecia because grade ≥3 events were not applicable. Percentages were calculated using available safety data for each adverse event; therefore, minor differences may occur because of rounding and missing data.Abbreviation: CTCAE, common terminology criteria for adverse events. Treatment-related adverse events by age group (<65 vs ≥65 years). Adverse events were graded according to CTCAE version 5.0. Values are shown as n (%). P-values refer to comparisons of grade ≥3 adverse events between age groups. P-values were not calculated for alopecia because grade ≥3 events were not applicable. Percentages were calculated using available safety data for each adverse event; therefore, minor differences may occur because of rounding and missing data. Abbreviation: CTCAE, common terminology criteria for adverse events. Discussion In this multinational real-world study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan, patients aged ≥65 years represented 1 quarter of the cohort. Compared with younger patients, older patients had more comorbidities, poorer ECOG performance status, and a higher number of prior palliative systemic therapy lines. Conversely, younger patients more frequently had documented BRCA1/2 pathogenic variants and visceral or central nervous system metastases. Despite these baseline differences, treatment exposure, response outcomes, and safety were broadly comparable between age groups. In unadjusted analyses, patients aged ≥65 years had longer OS and PFS; however, age was not independently associated with either endpoint after adjustment for key clinical and disease-related factors. These findings suggest that the observed survival differences were more likely related to baseline disease characteristics, metastatic burden, disease biology, and patient selection than to chronological age itself.16,17 Our results are consistent with subgroup analyses from the pivotal ASCENT trial, which suggested maintained efficacy and manageable toxicity of SG across age groups.9 Outcomes in our cohort were numerically lower than those reported in ASCENT, likely reflecting the broader and less selected nature of routine clinical practice, including patients with comorbidities, poorer performance status, and heterogeneous treatment histories. This distinction is particularly relevant for older adults, who are frequently underrepresented in clinical trials and may differ substantially from trial-eligible populations. The safety profile observed in our cohort was generally consistent with ASCENT and other real-world studies.3,18–22 Rates of grade ≥3 neutropenia were comparable between younger and older patients, and no clear signal of excess severe toxicity was observed in patients aged ≥65 years. Although older patients numerically more often required dose reductions and treatment delays, overall treatment exposure remained similar between age groups. These findings may suggest that individualized dose modification and supportive care can allow selected older patients to continue SG therapy; however, this interpretation should remain cautious because older-adult-centered toxicity outcomes were not systematically captured. Several real-world studies have evaluated SG in mTNBC, but most have not provided dedicated age-stratified analyses. In the Polish multicenter cohort by Püsküllüoğlu et al., median PFS and OS reached 5.2 and 9.5 months, respectively, consistent with the ASCENT trial.23 A recent Central European retrospective analysis also reported comparable outcomes in a broader regional population.24 Other international real-world analyses have similarly confirmed the clinical activity of SG outside clinical trials.19–22 Our study complements these reports by focusing specifically on age-stratified outcomes and by highlighting the need for better characterization of older adults receiving antibody-drug conjugates. The underrepresentation of older adults is not unique to studies of SG but reflects a broader evidence gap across modern mTNBC treatment modalities. Subgroup analyses of trials investigating other novel agents, including immune checkpoint inhibitors and antibody-drug conjugates, have included relatively few patients aged ≥70 years, with limited reporting of age-specific outcomes.25–27 Real-world studies of these therapies also rarely provide detailed age-stratified results, making it difficult to assess tolerability and outcomes in older populations.28,29 The apparent survival difference observed in unadjusted analyses may partly reflect differences in disease biology and metastatic patterns. Younger patients in our cohort more frequently had documented BRCA1/2 pathogenic variants and visceral or central nervous system metastases, which are established adverse prognostic factors. After adjustment for these and other clinically relevant variables, age was no longer independently associated with OS or PFS. These findings support the interpretation that chronological age alone is an insufficient surrogate for disease aggressiveness, treatment tolerance, or expected outcome. Prior studies have suggested that TNBC in older patients may represent a biologically heterogeneous group with molecular and clinical features distinct from those seen in younger patients.16,17 Jenkins and colleagues also demonstrated that TNBC in older women may include more diverse biological subtypes, further supporting the need to interpret age-related outcome differences in the context of tumor biology rather than age alone.30 Sensitivity analyses using an alternative age cutoff of 70 years did not show significant differences in OS or PFS. Analyses of patients aged ≥75 years were limited by the very small sample size and are therefore presented in the Supplementary Materials as descriptive findings only. This subgroup remains clinically important, as patients in this age range are more likely to experience frailty, competing mortality, polypharmacy, and treatment intolerance. However, the present study cannot provide reliable estimates of SG effectiveness or safety in patients aged ≥75 years. Geriatric assessment was performed in only a small minority of older patients, reflecting its limited implementation in routine oncology practice across participating centers. Exploratory analyses related to geriatric assessment are presented in the Supplementary Materials. Given the small number of assessed patients and the risk of selection bias, no conclusions can be drawn regarding the impact of geriatric assessment on SG outcomes in this cohort. Nevertheless, the low rate of geriatric assessment use underscores an important gap in routine care and supports guideline recommendations for broader integration of geriatric assessment in older adults receiving systemic cancer therapy.31–34 This study has several limitations. Its retrospective design carries an inherent risk of selection bias, including the possibility that older patients selected for SG had better baseline clinical status than the broader population of older adults with mTNBC. Treatment decisions, imaging intervals, response assessment, supportive care, G-CSF use, dose modification thresholds, and toxicity documentation may have varied across centers and countries. PFS should therefore be interpreted cautiously, as progression was assessed locally without centralized radiological review. Cause-specific mortality data were not systematically available, precluding breast cancer-specific survival analyses. Several variables particularly relevant to geriatric oncology, including frailty, functional status, cognition, falls, nutritional status, polypharmacy, social support, hospitalization, emergency visits, delirium, dehydration, and functional decline, were not consistently captured. Molecular and biomarker data were also incomplete, including a higher proportion of untested BRCA1/2 status among older patients. Despite these limitations, this study provides one of the largest real-world age-stratified analyses of SG in patients with mTNBC in Central Europe. The findings suggest that selected older adults treated with SG in routine clinical practice may achieve outcomes comparable to those of younger patients, with no clear signal of excess severe toxicity. Importantly, the data do not support chronological age itself as an independent predictor of survival after adjustment for clinical and disease-related factors. Prospective studies incorporating standardized geriatric assessment, detailed toxicity reporting, functional outcomes. and older-adult-centered endpoints are needed to better define the optimal use of SG in this population. Conclusions In this multinational real-world cohort, selected patients aged ≥65 years who received sacituzumab govitecan for mTNBC had outcomes at least comparable to those of younger patients, with no clear signal of excess severe toxicity. Although patients aged ≥65 years had longer OS and PFS in unadjusted analyses, age was not independently associated with survival outcomes after adjustment for relevant prognostic factors. These findings support individualized treatment decisions based on overall clinical status, disease characteristics, comorbidity burden, and patient preferences rather than chronological age alone. Prospective studies specifically designed for older adults with mTNBC are needed to validate these observations and optimize treatment strategies in this underrepresented population. Supplementary Material Contributor Information Aleksandra Konieczna, Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland. Małgorzata Pieniążek, Department of Oncology, Breast Unit Clinical Oncology Day Care Department, Wroclaw Medical University, Lower Silesian Comprehensive Cancer Center, Wroclaw 53-413, Poland. Justyna Żubrowska, Department of Clinical Oncology, Holy Cross Cancer Center, Kielce 25-734, Poland. Anna Polakiewicz-Gilowska, Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice 44-102, Poland. Renata Soumarová, Department of Oncology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague 100 34, Czech Republic. Miloš Holánek, Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, and Faculty of Medicine, Masaryk University, Brno 656 53, Czech Republic. Hana Študentová, Department of Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc 779 00, Czech Republic. Agnieszka Młodzińska, Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland. Karolina Winsko-Szczęsnowicz, Department of Clinical Oncology, M. Sklodowska-Curie Bialystok Oncology Center, Bialystok 15-027, Poland. Maja Lisik-Habib, Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz 95-513, Poland. Anika Pękala, Department of Proliferative Diseases, Nicolaus Copernicus Multidisciplinary Centre for Oncology and Traumatology, Lodz 95-513, Poland. Daniel Krejčí, Department of Oncology, First Faculty of Medicine, Charles University in Prague, and Bulovka University Hospital, Prague 180 81, Czech Republic. Jan Šustr, Department of Oncology and Radiotherapy, Faculty of Medicine in Pilsen, Charles University, and University Hospital Pilsen, Plzen 301 00, Czech Republic. Iveta Kolářová, Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove and University Hospital in Hradec Kralove, Charles University, Hradec Kralove 500 05, Czech Republic. Iwona Danielewicz, Department of Clinical Oncology with BCU, Pomeranian Hospitals, Gdynia 81-519, Poland. Magdalena Szymanik-Resko, Department of Clinical Oncology with BCU, Pomeranian Hospitals, Gdynia 81-519, Poland. Tomasz Ciszewski, Department of Metabolic Diseases and Immuno-oncology, Medical University of Lublin, Lublin 20-080, Poland. Lenka Rušinová, Department of Oncology, Stefan Kukura Hospital, Michalovce 071 01, Slovakia. Bogumiła Czartoryska-Arłukowicz, Department of Clinical Oncology, M. Sklodowska-Curie Bialystok Oncology Center, Bialystok 15-027, Poland. Aleksandra Łacko, Department of Clinical Oncology, Holy Cross Cancer Center, Kielce 25-734, Poland. Michał Jarząb, Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice 44-102, Poland. Marcin Kubeczko, Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice 44-102, Poland. Renata Pacholczak-Madej, Department of Gynecological Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow 31-115, Poland. Joanna Smok-Kalwat, Department of Clinical Oncology, Holy Cross Cancer Center, Kielce 25-734, Poland. Zbigniew Nowecki, Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland. Zuzana Bielčiková, Department of Oncology, First Faculty of Medicine, Charles University, and General University Hospital, Prague 128 08, Czech Republic. Miroslava Malejčíková, II. Oncology Clinic of LFUK, National Cancer Institute, Bratislava 833 10, Slovakia. Mirosława Püsküllüoğlu, Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow 31-115, Poland. Author contributions Aleksandra Konieczna (Conceptualization, Investigation, Methodology, Project administration, Writing—original draft), Małgorzata Pieniążek (Data curation, Methodology, Writing—review & editing), Justyna Żubrowska (Data curation, Investigation, Writing—review & editing), Anna Polakiewicz-Gilowska (Data curation, Methodology, Writing—review & editing), Renata Soumarová (Writing—review & editing), Miloš Holánek (Data curation, Methodology, Writing—review & editing), Hana Študentová (Data curation, Methodology, Writing—review & editing), Agnieszka Młodzińska (Writing—review & editing), Karolina Winsko-Szczęsnowicz (Data curation, Investigation, Writing—review & editing), Maja Lisik-Habib (Investigation, Writing—review & editing), Anika Pękala (Data curation, Writing—review & editing), Daniel Krejčí (Data curation, Methodology, Writing—review & editing), Jan Šustr (Investigation, Resources, Writing—review & editing), Iveta Kolářová (Writing—review & editing), Iwona Danielewicz (Investigation, Methodology, Writing—review & editing), Magdalena Szymanik-Resko (Formal analysis, Software, Writing—review & editing), Tomasz Ciszewski (Writing—review & editing), Lenka Rušinová(Writing—review & editing), Bogumiła Czartoryska-Arłukowicz (Writing—review & editing), Aleksandra Łacko (Writing—review & editing), Michał Jarząb (Writing—review & editing), Marcin Kubeczko (Writing—review & editing), Renata Pacholczak-Madej (Methodology, Resources, Writing—review & editing), Joanna Smok-Kalwat (Writing—review & editing), Zbigniew Nowecki (Writing—review & editing), Zuzana Bielčiková (Methodology, Writing—review & editing), Miroslava Malejcíková (Writing—review & editing), and Mirosława Püsküllüoglu (Conceptualization, Project administration, Writing—review & editing) Supplementary material Supplementary material is available at The Oncologist online. Funding The authors confirm that this study, including manuscript preparation and the decision to submit for publication, was conducted without any financial support, grants, or other external funding. Conflicts of interest A.K. has received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, AstraZeneca, and Gilead, and advisory board honoraria from Novartis and Gilead. M.P. has received travel support and lecture fees from Pfizer and Novartis, lecture fees from Gilead, and has served on an advisory board for Novartis. J.Ż. has received travel grants and lecture fees from MSD, Novartis, and AstraZeneca, and lecture fees from Pfizer, Swixx Biopharma, and Eli Lilly. A.P.-G. has received lecture honoraria and travel support from AstraZeneca, Roche, Novartis, Eli Lilly, Swixx Biopharma, Gilead, and Pfizer. R.S. has received honoraria and support from BMS, AstraZeneca, Pfizer, Novartis, Eli Lilly, MSD, Gilead, Janssen, Astellas, Servier, Accord, and GSK, including advisory board participation. M.H. has received travel and conference support from MSD, Gilead, Eli Lilly, and AstraZeneca; lecture and speaker’s fees from Novartis, Gilead, Eli Lilly, and Teva; and has served on advisory boards for AstraZeneca, Eli Lilly, and Gilead. H.Š. has received speaker’s fees and conference support from Novartis, MSD, Janssen, Astellas, Pfizer, Richter Gedeon, AstraZeneca, and Ipsen. A.M. has received lecture honoraria from Novartis, Swixx Biopharma, and Gilead, and travel support from Eli Lilly, Pfizer, and Novartis. K.W.-S. has received travel support and lecture honoraria from Roche, Eli Lilly, Novartis, Pfizer, Gilead, MSD, AstraZeneca, and Aurovitas, and has participated in clinical studies sponsored by MSD and Pfizer. M.L.-H. has received lecture honoraria from MSD, AstraZeneca, Johnson & Johnson, Roche, BMS, Astellas, Merck, and GSK. Anika Pękala declares no conflicts of interest. D.K. has received honoraria, congress fees, and travel support from MSD, AstraZeneca, Novartis, Eli Lilly, Roche, and Pfizer. J.Š. has received conference support from Gilead and MSD and speaker’s fees from AstraZeneca and MSD. I.K. has received honoraria and support from AstraZeneca, Novartis, MSD, Eli Lilly, Roche, Swixx Biopharma, and Gilead, including advisory board participation. Iwona Danielewicz declares no conflicts of interest. Magdalena Szymanik-Resko declares no conflicts of interest. T.C. has received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, Roche, Gilead, and AstraZeneca. L.R. declares no conflicts of interest. B.C.-A. has received travel grants and lecture fees from Eli Lilly, Novartis, Pfizer, AstraZeneca, Gilead, and Roche. A.Ł. has received honoraria and support from AstraZeneca, Pfizer, Novartis, Eli Lilly, Roche, and Gilead Sciences, including advisory board participation. M.J. has received conference support from Gilead and Roche, speaker’s fees from Novartis, Roche, Eli Lilly, Pfizer, Teva, Exact Sciences, and Mammotome, and has served on advisory boards for Novartis and Pfizer. M.K. has served on advisory boards for Novartis; has received speaker’s fees and conference support from Novartis, Roche, MSD, Pfizer, Eli Lilly, Teva, Amgen, Swixx Biopharma, AstraZeneca, and Gilead; and has participated in clinical trials sponsored by Roche, MSD, Novartis, Seagen, and Gilead. R.P.-M. has received travel grants from Accord and BMS, and lecture fees from AstraZeneca, BMS, MSD, GSK, Novartis, and Roche. J.S.-K. and Z.N. declare no competing interests relevant to this manuscript. Z.B. has received travel grants and lecture honoraria from AstraZeneca, MSD, Roche, Novartis, Eli Lilly, and Gilead. M.M. declares no competing interests relevant to this manuscript. M.P. has received travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Eli Lilly, Janssen, Gilead, Pierre Fabre and Amgen. Data availability The data underlying this article cannot be shared publicly due to privacy and ethical restrictions related to patient-level clinical data. The data will be shared on reasonable request to the corresponding author, subject to institutional and ethical approval. References Associated Data Supplementary Materials Data Availability Statement The data underlying this article cannot be shared publicly due to privacy and ethical restrictions related to patient-level clinical data. The data will be shared on reasonable request to the corresponding author, subject to institutional and ethical approval.